CellRight Technologies, a Tissue Regenix company, entered into an agreement granting Arthrex distribution rights to its BioRinse bone portfolio in Europe.
CartiHeal announced a study demonstrating that its Agili-CÂ implant promotes the regenerative capacity of articular cartilage defects in a human cadaveric ex-vivo model.
Spinal Elements received additional FDA 510(k) clearance for claims related to the macro-, micro- and nano-surface structure of its Ti-Bond® surface coating technology.
Titan Spine closed a round of Series B financing for an undisclosed amount. Proceeds will support product line additions, sales team expansion and accelerated R&D initiatives.